Selected research
Industry Research
Epigenome Analysis Industry Research Report 2026
Market perspective
The global Epigenome Analysis market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Epigenome Analysis market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Epigenome Analysis market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Epigenome Analysis market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Epigenome Analysis include Illumina, Merck, QIAGEN, F. Hoffmann-La Roche, Eisai, Abcam, Diagenode, Active Motif and Zymo Research Corporation, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Epigenome Analysis market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Epigenome Analysis.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Epigenome Analysis Market by Company
Illumina
Merck
QIAGEN
F. Hoffmann-La Roche
Eisai
Abcam
Diagenode
Active Motif
Zymo Research Corporation
Thermo Fisher Scientific
Cellcentric
Syndax
New England Biolabs
Epizyme
Domainex
Agilent Technologies
AsisChem
Enzo Life Sciences
EpiGentek Group
BioVision
Promega Corporation
GeneTex
Pacific Biosciences of California
Epigenome Analysis Segment by Type
DNA Methylation Analysis
Analysis of DNA Interactions
Chromatin Accessibility
Conformation Assays
Epigenome Analysis Segment by Application
Research Institutes
Pharmaceutical Companies
Biotechnology Companies
Others
Epigenome Analysis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epigenome Analysis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Epigenome Analysis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epigenome Analysis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Epigenome Analysis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- DNA Methylation Analysis
- Analysis of DNA Interactions
- Chromatin Accessibility
- Conformation Assays
Applications
- Research Institutes
- Pharmaceutical Companies
- Biotechnology Companies
- Others
Companies covered
- Illumina
- Merck
- QIAGEN
- F. Hoffmann-La Roche
- Eisai
- Abcam
- Diagenode
- Active Motif
- Zymo Research Corporation
- Thermo Fisher Scientific
- Cellcentric
- Syndax
- New England Biolabs
- Epizyme
- Domainex
- Agilent Technologies
- AsisChem
- Enzo Life Sciences
- EpiGentek Group
- BioVision
- Promega Corporation
- GeneTex
- Pacific Biosciences of California
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Epigenome Analysis by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 DNA Methylation Analysis
- 2.2.3 Analysis of DNA Interactions
- 2.2.4 Chromatin Accessibility
- 2.2.5 Conformation Assays
- 2.3 Epigenome Analysis by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Research Institutes
- 2.3.3 Pharmaceutical Companies
- 2.3.4 Biotechnology Companies
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Epigenome Analysis Breakdown Data by Type
- 3.1 Global Epigenome Analysis Historic Market Size by Type (2021-2026)
- 3.2 Global Epigenome Analysis Forecasted Market Size by Type (2027-2032)
4 Epigenome Analysis Breakdown Data by Application
- 4.1 Global Epigenome Analysis Historic Market Size by Application (2021-2026)
- 4.2 Global Epigenome Analysis Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Epigenome Analysis Market Perspective (2021-2032)
- 5.2 Global Epigenome Analysis Growth Trends by Region
- 5.2.1 Global Epigenome Analysis Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Epigenome Analysis Historic Market Size by Region (2021-2026)
- 5.2.3 Epigenome Analysis Forecasted Market Size by Region (2027-2032)
- 5.3 Epigenome Analysis Market Dynamics
- 5.3.1 Epigenome Analysis Industry Trends
- 5.3.2 Epigenome Analysis Market Drivers
- 5.3.3 Epigenome Analysis Market Challenges
- 5.3.4 Epigenome Analysis Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Epigenome Analysis Players by Revenue
- 6.1.1 Global Top Epigenome Analysis Players by Revenue (2021-2026)
- 6.1.2 Global Epigenome Analysis Revenue Market Share by Players (2021-2026)
- 6.2 Global Epigenome Analysis Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Epigenome Analysis Head Office and Area Served
- 6.4 Global Epigenome Analysis Players, Product Type & Application
- 6.5 Global Epigenome Analysis Manufacturers Established Date
- 6.6 Global Epigenome Analysis Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Epigenome Analysis Market Size (2021-2032)
- 7.2 North America Epigenome Analysis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Epigenome Analysis Market Size by Country (2021-2026)
- 7.4 North America Epigenome Analysis Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Epigenome Analysis Market Size (2021-2032)
- 8.2 Europe Epigenome Analysis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Epigenome Analysis Market Size by Country (2021-2026)
- 8.4 Europe Epigenome Analysis Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Epigenome Analysis Market Size (2021-2032)
- 9.2 Asia-Pacific Epigenome Analysis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Epigenome Analysis Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Epigenome Analysis Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Epigenome Analysis Market Size (2021-2032)
- 10.2 South America Epigenome Analysis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Epigenome Analysis Market Size by Country (2021-2026)
- 10.4 South America Epigenome Analysis Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Epigenome Analysis Market Size (2021-2032)
- 11.2 Middle East & Africa Epigenome Analysis Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Epigenome Analysis Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Epigenome Analysis Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Illumina
- 12.1.1 Illumina Company Information
- 12.1.2 Illumina Business Overview
- 12.1.3 Illumina Revenue in Epigenome Analysis Business (2021-2026)
- 12.1.4 Illumina Epigenome Analysis Product Portfolio
- 12.1.5 Illumina Recent Developments
- 12.2 Merck
- 12.2.1 Merck Company Information
- 12.2.2 Merck Business Overview
- 12.2.3 Merck Revenue in Epigenome Analysis Business (2021-2026)
- 12.2.4 Merck Epigenome Analysis Product Portfolio
- 12.2.5 Merck Recent Developments
- 12.3 QIAGEN
- 12.3.1 QIAGEN Company Information
- 12.3.2 QIAGEN Business Overview
- 12.3.3 QIAGEN Revenue in Epigenome Analysis Business (2021-2026)
- 12.3.4 QIAGEN Epigenome Analysis Product Portfolio
- 12.3.5 QIAGEN Recent Developments
- 12.4 F. Hoffmann-La Roche
- 12.4.1 F. Hoffmann-La Roche Company Information
- 12.4.2 F. Hoffmann-La Roche Business Overview
- 12.4.3 F. Hoffmann-La Roche Revenue in Epigenome Analysis Business (2021-2026)
- 12.4.4 F. Hoffmann-La Roche Epigenome Analysis Product Portfolio
- 12.4.5 F. Hoffmann-La Roche Recent Developments
- 12.5 Eisai
- 12.5.1 Eisai Company Information
- 12.5.2 Eisai Business Overview
- 12.5.3 Eisai Revenue in Epigenome Analysis Business (2021-2026)
- 12.5.4 Eisai Epigenome Analysis Product Portfolio
- 12.5.5 Eisai Recent Developments
- 12.6 Abcam
- 12.6.1 Abcam Company Information
- 12.6.2 Abcam Business Overview
- 12.6.3 Abcam Revenue in Epigenome Analysis Business (2021-2026)
- 12.6.4 Abcam Epigenome Analysis Product Portfolio
- 12.6.5 Abcam Recent Developments
- 12.7 Diagenode
- 12.7.1 Diagenode Company Information
- 12.7.2 Diagenode Business Overview
- 12.7.3 Diagenode Revenue in Epigenome Analysis Business (2021-2026)
- 12.7.4 Diagenode Epigenome Analysis Product Portfolio
- 12.7.5 Diagenode Recent Developments
- 12.8 Active Motif
- 12.8.1 Active Motif Company Information
- 12.8.2 Active Motif Business Overview
- 12.8.3 Active Motif Revenue in Epigenome Analysis Business (2021-2026)
- 12.8.4 Active Motif Epigenome Analysis Product Portfolio
- 12.8.5 Active Motif Recent Developments
- 12.9 Zymo Research Corporation
- 12.9.1 Zymo Research Corporation Company Information
- 12.9.2 Zymo Research Corporation Business Overview
- 12.9.3 Zymo Research Corporation Revenue in Epigenome Analysis Business (2021-2026)
- 12.9.4 Zymo Research Corporation Epigenome Analysis Product Portfolio
- 12.9.5 Zymo Research Corporation Recent Developments
- 12.10 Thermo Fisher Scientific
- 12.10.1 Thermo Fisher Scientific Company Information
- 12.10.2 Thermo Fisher Scientific Business Overview
- 12.10.3 Thermo Fisher Scientific Revenue in Epigenome Analysis Business (2021-2026)
- 12.10.4 Thermo Fisher Scientific Epigenome Analysis Product Portfolio
- 12.10.5 Thermo Fisher Scientific Recent Developments
- 12.11 Cellcentric
- 12.11.1 Cellcentric Company Information
- 12.11.2 Cellcentric Business Overview
- 12.11.3 Cellcentric Revenue in Epigenome Analysis Business (2021-2026)
- 12.11.4 Cellcentric Epigenome Analysis Product Portfolio
- 12.11.5 Cellcentric Recent Developments
- 12.12 Syndax
- 12.12.1 Syndax Company Information
- 12.12.2 Syndax Business Overview
- 12.12.3 Syndax Revenue in Epigenome Analysis Business (2021-2026)
- 12.12.4 Syndax Epigenome Analysis Product Portfolio
- 12.12.5 Syndax Recent Developments
- 12.13 New England Biolabs
- 12.13.1 New England Biolabs Company Information
- 12.13.2 New England Biolabs Business Overview
- 12.13.3 New England Biolabs Revenue in Epigenome Analysis Business (2021-2026)
- 12.13.4 New England Biolabs Epigenome Analysis Product Portfolio
- 12.13.5 New England Biolabs Recent Developments
- 12.14 Epizyme
- 12.14.1 Epizyme Company Information
- 12.14.2 Epizyme Business Overview
- 12.14.3 Epizyme Revenue in Epigenome Analysis Business (2021-2026)
- 12.14.4 Epizyme Epigenome Analysis Product Portfolio
- 12.14.5 Epizyme Recent Developments
- 12.15 Domainex
- 12.15.1 Domainex Company Information
- 12.15.2 Domainex Business Overview
- 12.15.3 Domainex Revenue in Epigenome Analysis Business (2021-2026)
- 12.15.4 Domainex Epigenome Analysis Product Portfolio
- 12.15.5 Domainex Recent Developments
- 12.16 Agilent Technologies
- 12.16.1 Agilent Technologies Company Information
- 12.16.2 Agilent Technologies Business Overview
- 12.16.3 Agilent Technologies Revenue in Epigenome Analysis Business (2021-2026)
- 12.16.4 Agilent Technologies Epigenome Analysis Product Portfolio
- 12.16.5 Agilent Technologies Recent Developments
- 12.17 AsisChem
- 12.17.1 AsisChem Company Information
- 12.17.2 AsisChem Business Overview
- 12.17.3 AsisChem Revenue in Epigenome Analysis Business (2021-2026)
- 12.17.4 AsisChem Epigenome Analysis Product Portfolio
- 12.17.5 AsisChem Recent Developments
- 12.18 Enzo Life Sciences
- 12.18.1 Enzo Life Sciences Company Information
- 12.18.2 Enzo Life Sciences Business Overview
- 12.18.3 Enzo Life Sciences Revenue in Epigenome Analysis Business (2021-2026)
- 12.18.4 Enzo Life Sciences Epigenome Analysis Product Portfolio
- 12.18.5 Enzo Life Sciences Recent Developments
- 12.19 EpiGentek Group
- 12.19.1 EpiGentek Group Company Information
- 12.19.2 EpiGentek Group Business Overview
- 12.19.3 EpiGentek Group Revenue in Epigenome Analysis Business (2021-2026)
- 12.19.4 EpiGentek Group Epigenome Analysis Product Portfolio
- 12.19.5 EpiGentek Group Recent Developments
- 12.20 BioVision
- 12.20.1 BioVision Company Information
- 12.20.2 BioVision Business Overview
- 12.20.3 BioVision Revenue in Epigenome Analysis Business (2021-2026)
- 12.20.4 BioVision Epigenome Analysis Product Portfolio
- 12.20.5 BioVision Recent Developments
- 12.21 Promega Corporation
- 12.21.1 Promega Corporation Company Information
- 12.21.2 Promega Corporation Business Overview
- 12.21.3 Promega Corporation Revenue in Epigenome Analysis Business (2021-2026)
- 12.21.4 Promega Corporation Epigenome Analysis Product Portfolio
- 12.21.5 Promega Corporation Recent Developments
- 12.22 GeneTex
- 12.22.1 GeneTex Company Information
- 12.22.2 GeneTex Business Overview
- 12.22.3 GeneTex Revenue in Epigenome Analysis Business (2021-2026)
- 12.22.4 GeneTex Epigenome Analysis Product Portfolio
- 12.22.5 GeneTex Recent Developments
- 12.23 Pacific Biosciences of California
- 12.23.1 Pacific Biosciences of California Company Information
- 12.23.2 Pacific Biosciences of California Business Overview
- 12.23.3 Pacific Biosciences of California Revenue in Epigenome Analysis Business (2021-2026)
- 12.23.4 Pacific Biosciences of California Epigenome Analysis Product Portfolio
- 12.23.5 Pacific Biosciences of California Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst